drugset
drugset / Trial / NCT02170766

Bioavailability of BIBR 953 ZW in Healthy Subjects

NCT02170766 ↗

Phase 1 Completed 48 enrolled Boehringer Ingelheim
RandomizedCrossoverOpen-labelTreatment

Summary

To assess the extend of absorption of 12.5, 25, 50 and 100 mg of BIBR 1048 free base with and without coadministration of 40 mg pantoprazole.

Timeline

Start
2000-10
Primary completion
2000-12
Completion
—

Drugs

EvaluationDrugModalityDoseRoute
Subject Dabigatran etexilate Unknown 12.5 mg Oral
Subject Dabigatran etexilate Unknown 25 mg Oral
Subject Dabigatran etexilate Unknown 50 mg Oral
Subject Dabigatran etexilate Unknown 100 mg Oral
Subject Pantoprazole Other / unclassified 40 mg —

Indications

No indication recorded.